Careers in Israel
Careers in USA
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Annual and Quarterly Reports
Therapeutic product discovery
In the information age
The next wave in immuno-oncology
Aug 07, 2017
Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month
Aug 02, 2017
Compugen Welcomes Paul Sekhri as its New Chairman of the Board
Our optimized process for predictive discovery of novel drug targets
Discovery & development of first-in-class monoclonal antibody therapeutics
CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...
CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...
CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
Sep 06, 2017
CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Aug 02, 2017
Compugen Second Quarter 2017 Conference Call
In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...
Click here for more info about partnering with Compugen